We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 01:00:00 |
From May 2019 to May 2024
By Yifan Wang
Zhejiang Jiuzhou Pharmaceutical Co. (603456.SH) on Thursday said it will acquire a unit of Novartis AG in eastern China for 790 million yuan (US$110.5 million).
Zhejiang Jiuzhou said it is buying all of Suzhou Novartis except its technology and drug-development assets. Suzhou Novartis is a branch of the Swiss pharmaceutical giant, which manufactures, develops and sells its drugs in China.
The acquisition will help Zhejiang Jiuzhou cement its position as a strategic supplier to Novartis, support its business development in Europe and the U.S., and improve its drug development and manufacturing capacities in China, it said.
Write to Yifan Wang at yifan.wang@wsj.com
(END) Dow Jones Newswires
September 04, 2019 21:09 ET (01:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
